- |||||||||| PK/PD data, Review, Journal: Pharmacokinetic considerations for angiogenesis inhibitors used to treat hepatocellular carcinoma: an overview. (Pubmed Central) - Nov 28, 2023
Anti-angiogenic drugs have different profiles in terms of bioavailability, metabolism, elimination and interindividual variability in their pharmacokinetics and effectiveness. More studies should be developed to address the intrinsic and extrinsic factors influencing pharmacokinetics parameters to improve the individual therapeutic response and, furthermore, to evaluate the benefit and the harm of systemic therapy for advanced HCC in selected patients with liver impairment.
- |||||||||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal, Adherence: Factors associated with lenvatinib adherence in thyroid cancer and hepatocellular carcinoma. (Pubmed Central) - Nov 27, 2023 The adherence rate for lenvatinib in Japanese patients with thyroid and hepatocellular carcinoma in real-world clinical practice was more than 90% in this study. Hypertension was a major reason for non-adherence, followed by hand-foot skin reactions and diarrhea.
- |||||||||| Avastin (bevacizumab) / Roche, Lenvima (lenvatinib) / Eisai, Merck (MSD), Tecentriq (atezolizumab) / Roche
Journal: Therapeutic Efficacy and Safety of Lenvatinib after Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma. (Pubmed Central) - Nov 25, 2023 There were some frequent adverse events (AEs) in patients treated with lenvatinib such as hypertension, fatigue, anorexia, proteinuria, and so on, but none directly caused death. In conclusion, lenvatinib after atezolizumab plus bevacizumab for unresectable HCC should be considered an effective treatment option.
- |||||||||| Avastin (bevacizumab) / Roche, Tecentriq (atezolizumab) / Roche
Journal, PD(L)-1 Biomarker, IO biomarker: Circulating CD8 Lymphocytes Predict Response to Atezolizumab-Bevacizumab in Hepatocellular Carcinoma. (Pubmed Central) - Nov 22, 2023 TRIM56, TRIM16, TRIM64 and Ki67 mRNAs were validated as up-regulated in responders versus non responders after 3 weeks from treatments start, providing a possible evidence of immune activation. Baseline CD8+ and CD8+PD-L1+ peripheral lymphocytes and early changes in CD8+PD1+ lymphocytes predict response to atezolizumab-bevacizumab providing non-invasive markers to complement clinical practice in the very early phases of treatment of HCC patients.
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial initiation date: Lenvatinib, Pembrolizumab, and Tumor Treating Fields (TTFields) for Second-line Treatment of Glioblastoma (clinicaltrials.gov) - Nov 22, 2023 P1/2, N=47, Not yet recruiting, Baseline CD8+ and CD8+PD-L1+ peripheral lymphocytes and early changes in CD8+PD1+ lymphocytes predict response to atezolizumab-bevacizumab providing non-invasive markers to complement clinical practice in the very early phases of treatment of HCC patients. Initiation date: Oct 2023 --> Jan 2024
- |||||||||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal: USP22-JMJD8 axis promotes Lenvatinib resistance in hepatocellular carcinoma. (Pubmed Central) - Nov 20, 2023 In the rescue experiment, the overexpression of JMJD8 could reduce the apoptosis induced by USP22 knockdown. In general, this study shows that USP22-JMJD8 is a drug design target for the mechanism of Lenvatinib resistance in HCC, which may improve the long-term efficacy of Lenvatinib.
- |||||||||| Tevimbra (tislelizumab-jsgr) / BeiGene, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment open, Trial initiation date, Metastases: Lenvatinib, Tislelizumab Combined With Gemcitabine and Cisplatin (GPLET) in the Treatment of Advanced Cholangiocarcinoma (clinicaltrials.gov) - Nov 18, 2023 P3, N=80, Recruiting, In general, this study shows that USP22-JMJD8 is a drug design target for the mechanism of Lenvatinib resistance in HCC, which may improve the long-term efficacy of Lenvatinib. Not yet recruiting --> Recruiting | Initiation date: Jun 2023 --> Oct 2023
- |||||||||| Review, Journal, Tumor mutational burden, IO biomarker: The Evolving Treatment Landscape of Medullary Thyroid Cancer. (Pubmed Central) - Nov 18, 2023
The best option for subsequent lines is to consider inclusion in clinical trials or alternatively other mTKIs such as sunitinib, sorafenib, lenvatinib, or pazopanib could be evaluated. New perspectives include next-generation RET inhibitors able to overcome resistance mechanisms responsible for disease progression to standard mTKIs and RET inhibitors, and immunotherapy for MTC presenting with high tumor mutational burden.
- |||||||||| Avastin (bevacizumab) / Roche, Lenvima (lenvatinib) / Eisai, Merck (MSD), Tecentriq (atezolizumab) / Roche
Clinical, Journal: Clinical Features and Outcomes of Conversion Therapy in Patients with Unresectable Hepatocellular Carcinoma. (Pubmed Central) - Nov 14, 2023 A comparison of the patients who achieved a partial response with and without conversion was evaluated using propensity score matching to reduce the confounding factors, showing a significant survival benefit in the conversion group (1208 [1064-NA] vs. 665 days, p < 0.01). Among the patients with u-HCC who were treated with LEN and Atezo + Bev, those with mALBI 1 + 2a and BCLC-B were likely to achieve conversion therapy with downstaging.
- |||||||||| volrustomig (MEDI5752) / AstraZeneca
Phase classification, Trial completion date, Trial primary completion date: A Study to Evaluate MEDI5752 and Axitinib in Subjects With Advanced Renal Cell Carcinoma (clinicaltrials.gov) - Nov 13, 2023 P1, N=179, Recruiting, [www.ClinicalTrials.gov], NCT04444167. Phase classification: P1b --> P1 | Trial completion date: Dec 2025 --> Aug 2027 | Trial primary completion date: Dec 2025 --> Aug 2027
- |||||||||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal: Impact of combining Lenvatinib with Transarterial chemoembolization for unresectable hepatocellular carcinoma. (Pubmed Central) - Nov 8, 2023 There were no significant differences in one or two year PFS rate or one year OS between groups (P>0.05), while the two years survival rate in the TACE+lenvatinib group was significantly higher than that in the TACE group (P<0.05). TACE combined with lenvatinib have a high clinical effective rate, with reduced AFP and VEGF levels, higher two year survival rate, and acceptable incidence of adverse events.
- |||||||||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment closed: Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid Tumors (clinicaltrials.gov) - Nov 7, 2023 P2, N=32, Active, not recruiting, TACE combined with lenvatinib have a high clinical effective rate, with reduced AFP and VEGF levels, higher two year survival rate, and acceptable incidence of adverse events. Recruiting --> Active, not recruiting
- |||||||||| Stivarga (regorafenib) / Bayer, Lenvima (lenvatinib) / Eisai, Merck (MSD), Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
Journal: Role of organic cation transporter 3 (OCT3) in the response of hepatocellular carcinoma to tyrosine kinase inhibitors. (Pubmed Central) - Nov 6, 2023 Other TKIs, such as regorafenib, lenvatinib, and cabozantinib can also interact with this transporter...In HCC samples, OCT3 was expressed at the PM of cancer cells, and its presence, detected in 26% of tumors, was associated with better outcomes in patients treated with sorafenib. In conclusion, analysis by immunohistochemistry of OCT3 in the PM of tumor cells may help to predict the response of HCC patients to sorafenib and potentially to other TKIs.
- |||||||||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal: Lenvatinib-Associated Fulminant Type 1 Diabetes Mellitus. (Pubmed Central) - Nov 5, 2023 By understanding these mechanisms better, we may be able to develop more effective treatment strategies for patients who do not respond to current therapies. No abstract available
- |||||||||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
Biomarker, Journal, Real-world evidence, PD(L)-1 Biomarker, IO biomarker, Real-world, Metastases: Real-world cohort study of PD-1 blockade plus lenvatinib for advanced intrahepatic cholangiocarcinoma: effectiveness, safety, and biomarker analysis. (Pubmed Central) - Nov 3, 2023 P=N/A PD-L1 expression and CA19-9 level appear to predict the treatment efficacy. IDH1 mutations might indicate a better treatment response.
- |||||||||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial completion date, Trial primary completion date, Metastases: Lenvatinib in Locally Advanced Invasive Thyroid Cancer (clinicaltrials.gov) - Nov 3, 2023 P2, N=30, Recruiting, Furthermore, the combination of MEX3C knockdown and Lenvatinib could offer a novel therapeutic avenue for HCC treatment. Trial completion date: Mar 2024 --> Mar 2025 | Trial primary completion date: Sep 2023 --> Dec 2024
|